Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster...

Area of Science:

• Neurology
• Pharmacology

Background:

• Cluster headache is a debilitating neurological condition.
• Acute treatment options for cluster headache require long-term safety and efficacy assessment.

Purpose of the Study:

• To evaluate the safety and efficacy of subcutaneous sumatriptan 6 mg for acute cluster headache treatment.
• To assess the long-term effects of frequent sumatriptan use in cluster headache patients.

Main Methods:

• Open-label study involving 138 patients over 24 months.
• Treatment of up to two cluster headache attacks daily with single 6 mg subcutaneous sumatriptan injections.
• Monitoring of adverse events, vital signs, ECG, laboratory parameters, and headache relief.

Main Results:

• 96% of treated attacks achieved headache relief within 15 minutes.
• Adverse events occurred in 28% of treatments, similar to migraine trials, with no increase upon frequent use.
• No significant adverse effects on vital signs, ECG, or lab parameters; no tachyphylaxis observed.

Conclusions:

• Subcutaneous sumatriptan 6 mg is well-tolerated for long-term acute cluster headache treatment.
• The drug demonstrates sustained efficacy without decreasing response speed or increasing attack frequency.
• This treatment offers a safe and effective option for managing cluster headache attacks.